After a clinical trial codenamed JUPITER, AstraZeneca’s anti-cholesterol drug, Crestor, could revolutionise the way heart disease is treated, say experts.

The trial was designed to see if Crestor could help people with normal levels of cholesterol but high levels of a protein connected to inflammation and risk of heart disease. About 18,000 people from 26 different countries participated in the trial and they all had acceptable levels of cholesterol and high levels of the inflammation marker, C-reactive protein (CRP). While half were put on the drug, the other were on a placebo. It was found that the combined risk of heart attack, stroke and heart-related death fell by nearly fifty per cent in the group taking Crestor.

Continue reading “AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment” »